

1. ['Gender Diversity and Digitalization are new catalysts for Pharma'](#) - Biospectrumindia.com

At the Organisation of Pharmaceutical Producers of India's (OPPI) annual HR summit on 'Sales Force Management', the role of diversity and digitalization in transforming the industry was actively discussed.

There was a cross-fertilisation of thoughts at the summit, amongst the distinguished speakers from various industries, who shared their experiences on skill development and building capability.

2. [Public health is best left to markets](#) - The Hindu Business Line

Game-changing inventions taken out of entrepreneurs' hands; slower innovation in healthcare technology and fewer ground-breaking treatments for patients worldwide: All these are possible outcomes of a combative report from the influential United Nations High Level Panel on Access to Medicines, which takes aim at the market-based system of drug development.

The panel argues that medicines would be cheaper if governments replaced markets in drug development, with a greater coordinating and resource-allocating role for the United Nations.

3. [Need to stop illegal e-sale of prescription drugs, says Bombay high court](#) - The Times of India

Steps will have to be taken to stop the illegal sale of schedule H and other drugs on websites and their television advertisements, said Bombay high court on Tuesday. Schedule H is a class of drugs that can be sold by retail only on prescription of a registered medical practitioner. The bench, headed by Justice Vidyasagar Sargar, heard a PIL filed last year by college lecturer Mayuri Patil seeking a ban on such sale as it is in violation of the Drugs and Cosmetics Act.

4. [437 Jan Aushadhi Kendra operational across India: Govt](#) - Business Standard

The government today said 437 Jan Aushadhi Kendras have become operational across the country and it plans to open 3,000 such centres by March 2017 to provide quality medicines at affordable rates. The maximum number of Jan Aushadhi Kendras are in Chhattisgarh at 122, followed by Uttar Pradesh 53, Maharashtra 35 and Kerala 33. Odisha and Punjab have 25 and 23 such centres. "As on September 20, 2016, 437 Pradhan Mantri Jan Aushadhi Kendras spread over 26 States/UTs are operational across the country. The government is committed to open 3000 PMJAK by March 2017 across India," an official statement said.

1. ['Gender Diversity and Digitalization are new catalysts for Pharma'](#) -

Biospectrumindia.com

2. [Public health is best left to markets](#) - The Hindu Business Line

3. [Need to stop illegal e-sale of prescription drugs, says Bombay high court](#) - The Times of India

4. [437 Jan Aushadhi Kendra operational across India: Govt](#) - Business Standard

5. [200 generic medicine centres to be launched in Bengaluru](#) - The Hindu

6. [Cipla, Wockhardt join global initiative on tackling drug resistant infections \(spot\)](#) - Business Standard

7. [Novartis gets Indian patent for skin cancer drug Tafinlar](#) - The Financial Express

8. [Breaking the mould: GSK picks Big Pharma's first female CEO](#) - Reuters.com

9. [Health ministry moves Supreme Court to transfer all FDC cases pending in various High Courts to SC](#) - Pharmabiz.com

10. [8th News Corp VCCircle Healthcare Investment Summit 2016 to be held in Mumbai](#) - Pharmabiz.com

5. [200 generic medicine centres to be launched in Bengaluru](#) – **The Hindu**

As many as 200 generic medicine centres will be launched in Bengaluru shortly. A Memorandum of Understanding will be entered into between the state and union government in Bengaluru on October 2 in this regard. According to an official release, this decision was announced at a discussion held between Union Minister for Chemicals and Fertilizers and Parliamentary Affairs H.N. Ananthkumar and Minister for Health and Family Welfare, Government of Karnataka, K.R. Ramesh Kumar on Monday.

6. [Cipla, Wockhardt join global initiative on tackling drug resistant infections \(spot\)](#) – **Business Standard**

Thirteen top pharmaceutical companies including Cipla and Wockhardt from India have formed an industry initiative on tackling drug resistant infections. The issue has been cause of concern amongst governments, policy makers and health activists and is being discussed at the United Nations General Assembly. A Bloomberg report quoting the World Bank said the spread of drug-resistant infections could mean a hit to the global economy even greater than that of the 2008 financial crisis as the emergence of so-called superbugs threatens growth in low-income countries.

Ahead of the meeting, thirteen companies have declared a roadmap on combating antimicrobial or antibiotic resistance. The companies said they are committed to reduce environmental impact in antibiotic production, monitor the usage of antibiotics, improve access and explore collaboration opportunities in research and development of new antibiotics, vaccines and diagnostics.

Similar reports-

- [Pharma companies Cipla & Wockhardt in global alliance to fight drug resistance](#) – The Economic Times
- [Drugmakers pledge to clean up antibiotic factories, curb overuse](#) – The Hindu Business Line

7. [Novartis gets Indian patent for skin cancer drug Tafinlar](#) – **The Financial Express**

Swiss pharma major Novartis AG has secured an Indian patent for its skin cancer drug Tafinlar, used in the treatment of metastatic melanoma- the most serious and life-threatening type of skin cancer that is associated with low survival rates. Tafinlar is a medicine that contains the active substance called Dabrafenib and it is used on its own or in combination with another medicine containing Trametinib on adults, to treat melanoma that has spread to other parts of the body or which cannot be removed by surgery. Novartis' agent filed the responses to FER in April 2016 and subsequently a hearing was offered in September first week. Having satisfied with Novartis' submission, Dr S Chattopadhyay, deputy controller of patents & designs, Kolkata, ordered the grant of patent.

8. [Breaking the mould: GSK picks Big Pharma's first female CEO](#) – **Reuters.com**

Emma Walmsley, GlaxoSmithKline's incoming CEO, breaks the mould as the first woman to lead a top global drugmaker and stands out among Big Pharma bosses as a consumer brands guru rather than a prescription medicines expert. But after six years at Britain's biggest drugmaker she is a confirmed GSK insider, which will disappoint those investors who had been hoping for a new broom from outside the company. The former classics and modern languages graduate from Oxford, who worked in marketing and management at French cosmetics group L'Oreal for 17 years before joining GSK, has her roots a long way from the pharmaceutical lab bench.

Also reported by-

- [GSK names Emma Walmsley as CEO-designate](#) – The Economic Times
- [GlaxoSmithKline names insider Emma Walmsley as new CEO](#) - The Financial Express

9. [Health ministry moves Supreme Court to transfer all FDC cases pending in various High Courts to SC – Pharmabiz.com](#)

The Union health ministry has moved Supreme Court, praying it to club and transfer all the petitions pending in various High Courts in the country filed by a large number of pharma companies and associations against the ministry's ban on 344 fixed dose combination (FDC) drugs in March this year. According to sources, the ministry's move in this regard is to avoid any kind of ambiguity on the issue that could arise from differing verdicts that might come from different High Courts as the case is pending in around 10 High Courts including Delhi High Court where the case has already been heard and an order is expected any time. In its petition, the ministry has requested the Supreme Court that all cases against the ban order being heard in High Courts across the country should be transferred to Supreme Court and be heard as a single case.

10. [8th News Corp VCCircle Healthcare Investment Summit 2016 to be held in Mumbai – Pharmabiz.com](#)

News Corp VCCircle, India's leading publisher of start-up and private equity news, data and information, and an integral part of global diversified media, news, education and information services group, News Corp, will be hosting 8th News Corp VCCircle Healthcare Investment Summit 2016 in Mumbai on September 21-22, 2016 at the ITC Maratha. This summit has over the years provided a platform for over two thousand attendees to meet, network and share their thoughts on shaping up India's healthcare industry.